Author:
Karatrasoglou Eleni A.,Lazaris Andreas C.,Spapis Vasileios,Zouki Dionysia N.
Publisher
Springer International Publishing
Reference66 articles.
1. Algaba F (2013) Immunohistochemistry in renal cell carcinoma. What’s new?-What’s new in uropathology? Handout. Working group symposium. 25th European Congress of Pathology. ESP
2. Algaba F, Akaza H, Lopez-Beltran A, Martignoni G et al (2011) Current pathologic keys of renal cell Carcinoma. Eur Urol 60(4):634–643
3. Armstrong AJ, Halabi S, Eisen T et al (2016) Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lancet Oncol 17:378–388
4. Bissler JJ, Kingswood JC, Radzikowska E et al (2016) Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial. Nephrol Dial Transplant 31(1):111–119
5. Campbell S, Lane B (2012) Malignant renal tumors. In: Kavoussi L, Novick A, Partin A, Peters C (eds) Campbell-Walsh urology, 10th edn. Saunders, Philadelphia, pp 1413–1474